Biotech Watchlist: Trevogrumab, A New Era in Obesity Management?

Targeting Fat Loss While Preserving Muscle Mass

Introducing Our Biotech Watchlist: High-Impact Drugs to Follow

Welcome to the first edition of this newsletter series, where we spotlight breakthrough therapies—whether in development or already on the market—that we believe could be game-changers for both patients and investors.

Each edition will dive into key drugs with disruptive potential, analyzing their clinical progress, competitive positioning, and stock-moving catalysts. Stay ahead of the curve as we track innovations that could reshape industries—and portfolios.

Trevogrumab & Obesity: A Missing Piece in the Puzzle?

As obesity treatment evolves beyond weight loss alone, Regeneron’s trevogrumab aims to redefine success by targeting muscle preservation alongside fat reduction. While GLP-1 receptor agonists like semaglutide and tirzepatide have demonstrated exceptional weight loss, up to 40% of lost weight comes from muscle mass, potentially impacting strength, metabolism, and long-term health.

Regeneron’s Phase 2 COURAGE trial, now fully enrolled, tests trevogrumab in combination with semaglutide (± garetosmab), investigating whether preserving lean mass alongside fat loss could offer a more sustainable and health-optimizing obesity treatment.

Why Trevogrumab?

• Potentially first-in-Class Anti-Myostatin Approach: Blocks myostatin (GDF8), a negative regulator of muscle growth, to preserve and enhance lean mass.

• Combination with Semaglutide: Aims to optimize weight loss composition, ensuring a higher fat-to-muscle loss ratio.

• Potential Market Differentiator: Could fill a critical gap in obesity treatment by preventing muscle deterioration, a known downside of GLP-1 therapies.

Key Upcoming Milestones

• Phase 2 COURAGE Readout: Expected 2H 2025, potentially as early as mid-Q3, with a key focus on fat-to-muscle loss dynamics.

• Path to Phase 3: If successful, Phase 3 trials could launch in 2026, paving the way for a 2028/29 market entry.

• Market Impact: A positive trial outcome could position trevogrumab as a key adjunct therapy alongside leading GLP-1 treatments, reshaping long-term obesity care.

With GLP-1-based therapies dominating the obesity landscape, trevogrumab’s ability to preserve muscle mass and enhance metabolic health could set a new standard for future obesity treatments.

Sunset from Kosciuszko Bridge, Hartaj Singh, March 2025

---

Upcoming Newsletter Events

March 2025: Video podcast featuring the Biotech Blueprint.

Early April 2025: Video podcast exploring how the biotech M&A and fund raising are going, with an Industry expert.

---

March Newsletter

Welcome to the Biotech Capital Compass! Your Guide to the Fast-Moving World of Biotech Investing.

If you’re an active investor, swing trader, or simply biotech-obsessed, you’ve come to the right place. Biotech Capital Compass delivers sharp analysis, market-moving insights, and actionable strategies tailored for those who want to stay ahead in this dynamic sector. Whether you’re trading biotech stocks daily, holding long-term positions, or just fascinated by the next breakthrough therapy, this newsletter is built for you.

We’re Leveling Up—Join the Inner Circle!

Starting January 2025, Biotech Capital Compass moved to a premium subscription model, following an incredible three-month free run in late 2024. If you’re serious about navigating the high-stakes biotech market, now is the time to get in—exclusive insights, deep-dive analysis, and smart trading strategies await.

Let’s Build This Together!

Subscribers, your feedback, comments, and ideas are what make this community thrive. Engage, ask, challenge, and share your insights—because the best biotech investors learn from each other. Let’s make this the go-to hub for those who want to decode the biotech landscape and capitalize on its biggest opportunities.

Ready to take your biotech investing to the next level? Let’s dive in!

Disclosures at end of note.

About the Author

Hartaj Singh brings over 30 years of experience in drug development, corporate strategy, hedge fund management, and biotech analysis. With a career spanning top investment banks, Hartaj has been a highly ranked analyst, known for providing astute guidance on biotech investments for over a decade. His deep sector knowledge, honed through years of navigating the biotech landscape, is now being put to use to help investors capitalize on biotech opportunities.